Semaglutide 10mg Research Peptide
Semaglutide is a long-acting glucagon-like peptide-1 receptor agonist (GLP-1 RA) developed by Novo Nordisk, approved for type 2 diabetes (Ozempic) and obesity (Wegovy). For research purposes, semaglutide is one of the most well-characterized GLP-1 receptor agonists available, with an extensive clinical trial database spanning over 10 years and multiple Phase 3 programs. This 10mg vial provides research-grade semaglutide at ≥99% purity, HPLC and MS/MS verified per batch.
Research Background
Semaglutide’s 94% structural homology to native GLP-1 combined with a C18 fatty acid side chain attachment enables a ~168-hour half-life through albumin binding. The SUSTAIN and STEP clinical trial programs generated an exceptionally detailed dataset across glycemic control, weight reduction, cardiovascular outcomes, and renal function. In the STEP 1 trial (NEJM, 2021), semaglutide 2.4mg achieved a mean weight reduction of 14.9% over 68 weeks versus 2.4% placebo — establishing a benchmark that subsequent compounds including retatrutide have sought to surpass.
Compound Specifications
- Format: Lyophilized powder
- Purity: ≥99% (HPLC verified)
- Quantity: 10mg per vial
- Storage: −20°C, protected from light
- Molecular Weight: 4113.6 Da
- CAS Number: 910463-68-2
Certificate of Analysis
All semaglutide vials are third-party tested by independent ISO-certified laboratories. HPLC and MS/MS validation performed per batch. COA available on request.
For research and laboratory use only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.
